Literature DB >> 21252206

Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease.

Tamar Farfel-Becker1, Einat B Vitner, Sarah N R Pressey, Raya Eilam, Jonathan D Cooper, Anthony H Futerman.   

Abstract

Gaucher disease (GD), the most common lysosomal storage disorder, is caused by a deficiency in the lysosomal enzyme glucocerebrosidase (GlcCerase), which results in intracellular accumulation of glucosylceramide (GlcCer). The rare neuronopathic forms of GD are characterized by profound neurological impairment and neuronal cell death, but little is known about the neuropathological changes that underlie these events. We now systematically examine the onset and progression of various neuropathological changes (including microglial activation, astrogliosis and neuron loss) in a mouse model of neuronopathic GD, and document the brain areas that are first affected, which may reflect vulnerability of these areas to GlcCerase deficiency. We also identify neuropathological changes in several brain areas and pathways, such as the substantia nigra reticulata, reticulotegmental nucleus of the pons, cochlear nucleus and the somatosensory system, which could be responsible for some of the neurological manifestations of the human disease. In addition, we establish that microglial activation and astrogliosis are spatially and temporally correlated with selective neuron loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252206     DOI: 10.1093/hmg/ddr019

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  40 in total

Review 1.  The clinical management of Type 2 Gaucher disease.

Authors:  Karin Weiss; Ashley Gonzalez; Grisel Lopez; Leah Pedoeim; Catherine Groden; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2014-11-14       Impact factor: 4.797

Review 2.  Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease.

Authors:  Masoomeh Khalifeh; George E Barreto; Amirhossein Sahebkar
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

Review 3.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

Review 4.  Blood-brain barrier structure and function and the challenges for CNS drug delivery.

Authors:  N Joan Abbott
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

5.  Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels.

Authors:  Oshrit Ben-David; Yael Pewzner-Jung; Ori Brenner; Elad L Laviad; Aviram Kogot-Levin; Itai Weissberg; Inbal E Biton; Reut Pienik; Elaine Wang; Samuel Kelly; Joseph Alroy; Annick Raas-Rothschild; Alon Friedman; Britta Brügger; Alfred H Merrill; Anthony H Futerman
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

6.  Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder.

Authors:  Chiara Di Malta; John D Fryer; Carmine Settembre; Andrea Ballabio
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

7.  Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Samuel L Kelly; Jessica R Bame; Jingjing Duan; Vera Shinder; Alfred H Merrill; Kostantin Dobrenis; Anthony H Futerman
Journal:  Hum Mol Genet       Date:  2013-09-24       Impact factor: 6.150

8.  Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

Authors:  Lama M Chahine; Judy Qiang; Emily Ashbridge; James Minger; Dora Yearout; Stacy Horn; Amy Colcher; Howard I Hurtig; Virginia M-Y Lee; Vivianna M Van Deerlin; James B Leverenz; Andrew D Siderowf; John Q Trojanowski; Cyrus P Zabetian; Alice Chen-Plotkin
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

Review 9.  The role of inflammation in sporadic and familial Parkinson's disease.

Authors:  Michela Deleidi; Thomas Gasser
Journal:  Cell Mol Life Sci       Date:  2013-05-12       Impact factor: 9.261

Review 10.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.